- Home
- PRFX vs ENSC Comparison
PRFX vs ENSC Comparison
Compare PRFX & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- ENSC
- Stock Information
- Founded
- PRFX 2007
- ENSC 2003
- Country
- PRFX Israel
- ENSC United States
- Employees
- PRFX N/A
- ENSC N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- PRFX Health Care
- ENSC Health Care
- Exchange
- PRFX Nasdaq
- ENSC Nasdaq
- Market Cap
- PRFX 3.6M
- ENSC 3.4M
- IPO Year
- PRFX 2020
- ENSC N/A
- Fundamental
- Price
- PRFX $2.06
- ENSC $2.38
- Analyst Decision
- PRFX Hold
- ENSC
- Analyst Count
- PRFX 1
- ENSC 0
- Target Price
- PRFX N/A
- ENSC N/A
- AVG Volume (30 Days)
- PRFX 55.9K
- ENSC 455.1K
- Earning Date
- PRFX 06-20-2025
- ENSC 05-13-2025
- Dividend Yield
- PRFX N/A
- ENSC N/A
- EPS Growth
- PRFX N/A
- ENSC N/A
- EPS
- PRFX N/A
- ENSC N/A
- Revenue
- PRFX N/A
- ENSC $6,224,081.00
- Revenue This Year
- PRFX N/A
- ENSC N/A
- Revenue Next Year
- PRFX N/A
- ENSC $1,381.48
- P/E Ratio
- PRFX N/A
- ENSC N/A
- Revenue Growth
- PRFX N/A
- ENSC 256.35
- 52 Week Low
- PRFX $1.68
- ENSC $1.62
- 52 Week High
- PRFX $18.17
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- PRFX 51.59
- ENSC 49.99
- Support Level
- PRFX $1.93
- ENSC $2.12
- Resistance Level
- PRFX $2.11
- ENSC $2.57
- Average True Range (ATR)
- PRFX 0.10
- ENSC 0.21
- MACD
- PRFX 0.03
- ENSC 0.04
- Stochastic Oscillator
- PRFX 80.77
- ENSC 53.87
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.